A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol after One Year of Therapy in Patients with Early Rheumatoid Arthritis.
Arthritis & rheumatology（2017）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined